Pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has achieved an 80% cure rate as a result of a risk-adapted therapy largely based on minimal residual disease (MRD) monitoring. However, relapse is still the most frequent adverse event, occurring mainly in the patients with intermediate MRD levels (intermediate risk, IR), emphasizing the need for new prognostic markers. We analyzed the prognostic impact of cytokine receptor-like factor 2 (CRLF2) over-expression and P2RY8-CRLF2 fusion in 464 BCP-ALL patients (not affected by Down syndrome and BCR-ABL negative) enrolled in the AIEOP-BFM ALL2000 study in Italy. In 22/464 (4.7%) samples, RQ-PCR showed CRLF2 over-expression (X20 times higher than the overall median). P2RY8-CRLF2 fusion was detected in 22/365 (6%) cases, with 10/22 cases also showing CRLF2 over-expression. P2RY8-CRLF2 fusion was the most relevant prognostic factor independent of CRLF2 over-expression with a threefold increase in risk of relapse. Significantly, the cumulative incidence of relapse of the P2RY8-CRLF2 þ patients in the IR group was high (61.1% ± 12.9 vs 17.6% ± 2.6, Po0.0001), similar to high-risk patients in AIEOP-BFM ALL2000 study. These results were confirmed in a cohort of patients treated in Germany. In conclusion, P2RY8-CRLF2 identifies a subset of BCP-ALL patients currently stratified as IR that could be considered for treatment intensification.
INTRODUCTION
The cure rate of new diagnosed pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is higher than 80%. However, the probability of survival of patients who relapse after treatment is only 30%. In the AIEOP-BFM ALL2000 study, risk group stratification was largely based on minimal residual disease (MRD) monitoring as a measure of early response to therapy. Approximately, 30% of patients were at standard risk (SR), 55% at intermediate risk (IR) and 15% at high risk (HR) of relapse. In spite of the risk-adapted therapy, the majority of relapses occur in the large heterogeneous IR group. 1 Therefore, the identification of disease features with prognostic values within current risk groups remains a formidable challenge in childhood ALL.
Chromosomal translocations that were identified as key factors in the pathogenesis of ALL and provided essential prognostic hallmarks have been incorporated in patient risk stratification. There is a need to identify which of the recently discovered genetic alterations have the potential to improve patient stratification 2 as well as for the development of targeted therapeutic approaches. [3] [4] [5] In a subset of BCP-ALL patients without known chromosomal aberrations, two genomic abnormalities have been reported that involve Ikaros (IKZF1) 6, 7 and cytokine receptor-like factor 2 (CRLF2) [8] [9] [10] [11] [12] [13] genes. The latter abnormality includes small deletions within the pseudoautosomal region (PAR1) of the sex chromosomes as well as the translocation of this region to the IGH@ locus on chromosome 14. Several studies have provided evidence for the mechanistic basis of the over-expression of CRLF2 as a consequence of these chromosomal abnormalities. 8, 10 PAR1 deletion juxtaposes the first non-coding exon of P2RY8 to the first exon of CRLF2, leading to CRLF2 expression driven by the promoter of P2RY8. The translocation of PAR1 region to IGH@ locus, however, brings CRLF2 under the control of IGH@ enhancer elements. Elevated CRLF2 expression was found to be associated with IKZF1 deletions and activating JAK2 or CRLF2 point mutations. [10] [11] [12] 14 CRLF2 rearrangements were shown to be correlated with poor outcome in BCP-ALL patients, 12, 14 but it is still under debate whether this prognostic value is associated to CRLF2 overexpression or to specific CRLF2 aberrancies. Moreover, CRLF2 aberrations were not proven to bear significant prognostic value in children with ALL treated on UK protocols. 13 Here, we present data on the incidence and prognostic impact of CRLF2 over-expression, specifically P2RY8-CRLF2 fusion, at diagnosis in 464 Italian BCP-ALL children treated with the protocol of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) and Berlin-Frankfurt-Munster (BFM) group ('AIEOP-BFM ALL2000 protocol') and the potential impact of P2RY8-CRLF2 fusion within MRD-based subgroups.
We also present data on CRLF2 over-expression and P2RY8-CRLF2 fusion at BCP-ALL relapse and speculate on P2RY8-CRLF2 as a secondary event in disease progression.
PATIENTS AND METHODS Patients
BCP-ALL patients consecutively enrolled in the AIEOP-BFM ALL2000 study in AIEOP Centers from February 2003 to July 2005, not affected by Down syndrome (DS) nor Philadelphia chromosome positive (Ph þ ), were included in the study cohort. CRLF2 expression was analyzed in 464 patients at diagnosis and in 33 paired diagnosis and relapse samples, while P2RY8-CRLF2 rearrangement was tested in 365 patients at diagnosis and in 26 paired diagnosis and relapse samples for which leftover RNA was available. IGH@-CRLF2 translocation was screened in 8 out of 12 patients who were positive for CRLF2 over-expression (X20 times higher than overall median) but negative for P2RY8-CRLF2 fusion at diagnosis. DNA was available from 34 patients positive for CRLF2 over-expression or P2RY8-CRLF2 fusion at diagnosis, and the following were analyzed: CRLF2 mutations (in 25 out of 34 patients), JAK2 mutations (in 32 out of 34 patients) and IKZF1 deletions (in 33 out of 34 patients). CRLF2 and JAK2 mutations were also analyzed in 6 and 32 paired diagnosis and relapse samples, respectively.
The clinical characteristics of the analyzed patients compared with those not analyzed (AIEOP-BFM ALL2000 study patients diagnosed between September 2000 and July 2006) are shown in Supplementary Table 1 , and their event-free survival (EFS) curve is shown in Supplementary Figure 1a . Details of the study cohort are shown in the Supplementary Materials. In addition, 194 SR and 286 IR consecutive patients (non-DS and Ph À ) enrolled in the AIEOP-BFM ALL2000 study and treated in German Centers (BFM-G) 12 were analyzed by reverse transcriptase PCR (RT-PCR) for P2RY8-CRLF2 rearrangement, as a validation cohort.
Rank (464 pts)
Informed consent to participate in the study was obtained for all patients by parents or legal guardians. Risk group definitions and final stratification, treatment outlines, details and differences between AIEOP and BFM were previously reported 15 and briefly summarized below.
Protocol stratification
Patient risk groups were defined as follows. The HR group included patients with any of the following criteria: t(4;11) or MLL/AF4, prednisone poor response (X1000 blasts/ml on day 8 peripheral blood after 7 days of prednisone and one dose of intrathecal methotrexate on day 1), inability to achieve clinical remission after induction phase IA and high burden (X10 Poor outcome of P2RY8-CRLF2 in childhood ALL C Palmi et al using two sensitive markers (X1 Â 10 À 4 ) at both day 33 and day 78. The IR group included the remaining patients, and those not evaluated by PCR-MRD. Details of PCR-MRD are reported in the Supplementary Materials.
Quantitative expression of CRLF2
CRLF2 transcript levels on diagnostic and relapse samples were analyzed using TaqMan Gene Expression Assay Hs00913509_s1 (Applied Biosystems, Foster City, CA, USA); the housekeeping GUS gene transcript was tested as an internal control by using Universal Probe Library System (Roche Diagnostics, Basel, Switzerland), following the manufacturer's instructions. 16 Optimal primers and probe for GUS amplification were selected using the Roche ProbeFinder software (https://www.roche-appliedscience. com/sis/rtpcr/upl). Each cDNA sample (20 ng RNA equivalent) was tested in duplicate (Ct range between replicates o1.5). The amplification reaction was performed on the 7900HT FAST Real Time PCR System instrument (Applied Biosystems) with the following protocol: initial step at 95 1C for 10 min, then 50 cycles at 95 1C for 15 s and at 60 1C for 1 min.
Relative gene expression (indicated as fold change) was quantified by the 2 À DDCt method. 17 The DDCts were calculated by subtracting the median of the DCt of all the (n ¼ 464) tested patients at diagnosis to the DCt of each sample.
CRLF2 aberrations
The presence of the fusion transcript P2RY8-CRLF2 was investigated by RT-PCR. The patients analyzed at diagnosis were representative of the entire study cohort (Supplementary Table 2 and Supplementary Figure 1b) . In order to verify that the RT reaction worked properly, the house-keeping gene Abelson tyrosine kinase (ABL) expression was tested in parallel for each cDNA sample. RT-PCR for P2RY8-CRLF2 was performed using primers designed in the first exon of P2RY8 (5 0 -GGACAGATGGAACTGGAAGG-3 0 ) and the third exon of CRLF2 (5 0 -GTCCCATTCCTGATGGAGAA-3 0 ), giving rise to a PCR fragment of B511 bp. Amplification conditions were: initial denaturation at 94 1C for 2 min; 40 PCR cycles: denaturation at 94 1C for 30 s, annealing at 63 1C for 30 s, extension at 72 1C for 1 min and final extension at 72 1C for 10 min (PCR reagents from Roche).
RT-PCR to detect the P2RY8-CRLF2 fusion in the BFM-G cohort was performed as previously described. 12 IGH@-CRLF2 translocation was inquired by fluorescence in situ hybridization (FISH) on interphase nuclei using the Vysis LSI IGH Dual Color BreakApart Rearrangement Probe (Abbott Molecular, Abbott Park, IL, USA) and the CEP (chromosomes enumeration probes) DNA FISH Probe to detect chromosome X (Abbott Molecular). The nuclei were counterstained with DAPI (4 0 ,6-diamino-2-phenylindol). Results were recorded using a fluorescence Leica DMRB microscope fitted with a Â 100/1.30 oil objective, CCD camera and digital imaging software from Metasystem (ISIS, FISH imaging system).
To identify CRLF2 mutations, intronic primers of human CRLF2 sequence (accession number NM_022148.2) were used to amplify exons 1-6 of the gene with PCR. 11 Fragments were analyzed by denaturing high-performance liquid chromatography (WAVE, Transgenomic, Omaha, NE, USA). Fragments with abnormal chromatography patterns were sequenced.
Other genetic aberrations
High resolution melting (HRM) analysis was performed to identify JAK2 mutations in exon 16 using High Resolution Melting Master (Roche Diagnostics), following the manufacturer's instructions. In detail 20 ng of DNA was amplified in a final volume of 20 ml with 10 ml of Resolution Melting master mix (Roche Diagnostics), 2.8 ml of magnesium chloride, donors was used as a wild-type reference, whereas DNA from the MUTZ5 human cell line (DSMZ), carrying R683G Jak2 mutation, was used as a positive control. All the fragments with abnormal melting profile were sequenced. In particular, 200 ng of DNA samples positive for HRM analysis were amplified using 2. The PCR products were cloned by the Zero Blunt PCR Cloning Kit (Invitrogen, Carlsbad, CA, USA), following the manufacturer's instructions, and then sequenced using the ABI-3130 Genetic Analyzer instrument (Applied Biosystems).
IKZF1 deletions were investigated by Multiplex Ligation-dependent Probe Amplification (MLPA) technique using the Salsa MLPA kit P335-A3 ALL-IKZF1 kit (MRC-Holland, Amsterdam, the Netherlands), according to the manufacturer's instructions. Samples of pediatric ALL patients in complete remission were used as wild-type controls. The fragments were separated with the ABI-3130 Genetic Analyzer instrument (Applied Biosystems) and the data analyzed using Coffalyser software (http://old. mlpa.com/coffalyser).
Statistical analysis EFS and survival were calculated from the date of diagnosis to the date of event, which for EFS was resistance, relapse, death or second malignant neoplasm, whichever occurred first, and for survival was death from any cause. EFS and survival curves at 5 years were estimated according to Kaplan-Meier, and compared according to log-rank test. Cumulative incidence of relapse (CIR)
The Cox regression model was applied to evaluate the prognostic value of P2RY8-CRLF2 fusion and hiCRLF2 expression on the cause-specific hazard of relapse after adjusting by main prognostic features: sex, age, white cell count and MRD.
Follow-up was updated in February 2010.
RESULTS
CRLF2 aberrations at diagnosis CRLF2 expression, evaluated by real-time quantitative (RQ)-PCR on 464 pediatric BCP-ALL patients at diagnosis, ranged from 0.006-to 810-fold change compared to the overall median value (Figure 1a) . Outcome was evaluated within subgroups defined by different categories of CRLF2 expression. In particular, we evaluated potential cut-points starting from five times the overall median value and moving by steps of 5. The lowest threshold for CRLF2 expression showing a significant difference in CIR between two groups was 20 times the median that was then adopted as cut-point (Supplementary Figure 2) . Higher values of the threshold did not show an increase in discriminating power of the CIR for the two groups separated by the threshold. Twenty-two patients (4.7%) presented an expression higher than 20 times (hiCRLF2).
The P2RY8-CRLF2 fusion was detected in 22 patients of the 365 cases analyzed (6.0%). In all, 10 of them were also hiCRLF2 tested for the deletion, 50.0%), whereas the remaining 12 cases presented low levels of CRLF2 expression (less than 20 times the median, range: 0.006-18.5, 'loCRLF2'; Figure 1a ). Within the hiCRLF2 group, only one out of eight (negative for P2RY8-CRLF2) was positive for the IGH@ translocation (Figure 1b) . We observed JAK2 mutations in 3/10 hiCRLF2 P2RY8-CRLF2 positive patients, in 1/12 hiCRLF2 P2RY8-CRLF2 negative patients and 1/11 loCRLF2 P2RY8-CRLF2 positive patients (two R683G, one R683S and two insertion mutations: L681-I682insGEEL and T705delinsRWE). IKZF1 deletions were detected in 5/22 hiCRLF2 patients, 3 associated with P2RY8-CRLF2 fusion, and in 2/11 cases positive for P2RY8-CRLF2 but loCRLF2. The CRLF2 F232C mutation was detected in two hiCRLF2 patients, positive for both P2RY8-CRLF2 and IKZF1 deletions (Figures 1b, c and d) .
Clinical characteristics of patients positive for CRLF2 aberrations at diagnosis are described in Table 1 and in Supplementary Results.
All patients with P2RY8-CRLF2 fusion had DNA index o1.16, while 5/22 hiCRLF2 patients were classified as high hyperdiploid (Table 1 ).
All hiCRLF2 patients were negative for the recurring chro mosomal translocations t(4;11) and t(12;21). In particular, by regression analysis t(12;21) and CRLF2 expression show a significant negative correlation.
Prognostic impact of CRLF2 over-expression and P2RY8-CRLF2 fusion at diagnosis HiCRLF2 patients have a significantly inferior EFS (62.9%±10.5 vs 82.6% ± 1.8, P ¼ 0.05) and increased CIR (37.1% ± 10.5 vs 15.2% ± 1.7, P ¼ 0.02) compared with loCRLF2 patients. All the eight events in hiCRLF2 patients were relapses (Figures 2a and b) . The 5-year survival estimates were 85.9%±7.6 and 92.1%±1.3, respectively (P ¼ 0.35; Figure 3a) .
In all, 9 out of the 22 patients carrying P2RY8-CRLF2 fusion experienced relapse. Kaplan-Meier analysis revealed an inferior EFS (5-year EFS of 57.2% ± 10.9 vs 83.5% ± 2.0, P ¼ 0.004) and increased CIR (42.8% ± 10.9 vs 14.5% ± 1.9, P ¼ 0.001) for patients carrying the fusion gene (Figures 2c and d) . The 5-year survival estimates were significantly different, 80.9%±8.6 and 93.4%±1.4, respectively (P ¼ 0.04; Figure 3b) .
The worst outcome (EFS 37.5% ± 16.1 and CIR 62.5% ± 16.1) was observed for patients with the combination of hiCRLF2 and P2RY8-CRLF2 fusion, while hiCRLF2 patients who are negative for P2RY8-CRLF2 fusion seem to have an outcome comparable with patients lacking CRLF2 over-expression and fusion. Twelve patients were loCRLF2 and positive for P2RY8-CRLF2 fusion, three of whom relapsed (Figures 4a and b) .
Cox model analysis was performed to assess the relative prognostic value of P2RY8-CRLF2 fusion and hiCRLF2 expression after adjusting for main prognostic features (Table 2) . Results show that P2RY8-CRLF2 fusion retains prognostic significance with a threefold increase in the risk of relapse for positive versus negative patients (hazard ratio 3.30; 95% CI 1.29-8.48; P ¼ 0.01), while hiCRLF2 is not an independent prognostic factor (hazard ratio 1.05; 95% CI 0.37-2.97; P ¼ 0.93).
Outcome and risk group We further analyzed the prognostic value of P2RY8-CRLF2 fusion separately within SR and IR patient groups. P2RY8-CRLF2 fusion was similarly distributed within the two non-HR subgroups, being found in 6 out 106 SR patients (5.7%) and 15 out of 229 IR patients (6.7%; Table 1 ). However, none of the 6 P2RY8-CRLF2-positive SR patients relapsed (Figure 5a ), while 9 out of 15 cases in the IR group relapsed with a significant difference in the CIR (61.1% ± 12.9 vs 17.6% ± 2.6, Po0.0001; Figure 5b ), and in survival (72.7% ± 11.7 vs 93.1% ± 1.8, P ¼ 0.005; Figure 3c ). EFS curves are provided as Supplementary Figure 3 . Four of the nine relapses had BM localization, three were extramedullary and two combined (compared with only 6/39 extramedullary relapses in the P2RY8-CRLF2-negative IR patients).
In order to validate those findings, we analyzed the prognostic value of P2RY8-CRLF2 fusion for SR and IR patients enrolled in the AIEOP-BFM ALL2000 study and treated in German Centers (BFM-G). 12 In the BFM-G cohort, 2 out of 8 SR patients carrying the fusion experienced relapse, whereas 6 relapses out of 11 IR patients were observed (Figures 5c and d) . In the same BFM-G cohort, IR patients positive for P2RY8-CRLF2 fusion showed a significant higher CIR than patients without the fusion (54.5%±15 vs 10.7%±1.9, Po0.0001). Two of the six relapses had BM localization, three were extramedullary and one combined (compared with 10/31 extramedullary relapses in the P2RY8-CRLF2-negative IR patients).
BFM-G SR patients with or without the fusion have a CIR of 25.0% ± 15.3 vs 5.6% ± 1.7, P ¼ 0.05. Thus, apparently even in the BFM-G cohort, the SR patients who are positive for the fusion have a lower incidence of relapse than IR patients.
CRLF2 expression and genomic aberrations at relapse Thirty-three paired diagnostic and relapse specimens were analyzed for CRLF2 expression level. Samples at relapse showed a median value of CRLF2 expression two times higher than the respective samples at diagnosis (2.60 vs 1.25; Figure 6a ). The relapse sample with the highest CRLF2 expression level was the only sample positive for both P2RY8-CRLF2 rearrangement and JAK2 mutation (L681-I682insLR). Two P2RY8-CRLF2-positive patients at diagnosis lost the rearrangement at relapse and no de novo P2RY8-CRLF2 fusion was detected. CRLF2 mutations remained stable at relapse, while JAK2 mutations were lost in 1/34 patients at relapse (2.9%), acquired in 2/34 cases (5.9%) and in 1/34 case the mutation was different between diagnosis and relapse (respectively, R683G and L681-I682insRD; Figure 6b ). Detailed description of CRLF2-expression level and genomic aberrations of diagnosis/relapse pairs is shown in Supplementary  Table 3 .
DISCUSSION
In childhood ALL, risk-adjusted therapy has brought about impressive improvements of survival rates during the last decades. In this context, clinicians and researchers have two major objectives: to find new prognostic markers to identify upfront patients with high probability to relapse, 1, 5 including relapses during long-term follow-up, and to recognize good prognostic features that can be used to guide treatment-intensity reductions, aiming to spare children from acute and long-term side effects. 15 Although the advent of MRD monitoring has revolutionized the stratification approach of the risk-based treatments, 15, 18 new genomic discoveries are expected to be very useful, for recognizing previously undetectable subgroups of childhood ALL patients with specific risk levels, thus complementing MRD.
Here, for the first time, we report the incidence and prognostic relevance of CRLF2 over-expression and P2RY8-CRLF2 rearrangement in a study cohort of MRD-stratified childhood BCP-ALL, treated in Italy with the AIEOP-BFM ALL2000 protocol, excluding the confounding effect of DS and Ph þ subgroup of patients, Poor outcome of P2RY8-CRLF2 in childhood ALL C Palmi et al which had been included in other studies. 8, [10] [11] [12] [13] A high CRLF2 expression (defined as an expression level 20 times higher than the median expression of all patients analyzed) was detected in about 5% of patients, while the incidence of the P2RY8-CRLF2 fusion was estimated as 6%, which is in agreement with the incidence found in other cohorts with similar Caucasian composition. 12, 13 Importantly, for the first time, we observed that the P2RY8-CRLF2 fusion was not only found among patients with hiCRLF2 expression but also among patients with loCRLF2 expression. In the case of patients who are positive for the P2RY8-CRLF2 fusion but with low expression of CRLF2, we might speculate that the deletion is present in subclones of the leukemic blast cell population. The latter would be consistent with the marked subclonal heterogeneity in ALL, 19, 20 but further experiments will be necessary to show this.
The lack of absolute correlation between CRLF2 fusion and over-expression prompted us to explore the prognostic impact of both P2RY8-CRLF2 fusion and CRLF2 over-expression, alone and in combination.
Both hiCRLF2 and P2RY8-CRLF2 fusion were associated with a higher relapse rate. As already reported 12, 13 late relapses were prevalent, occurring mostly after the end of the 2-year treatment. Compared to the distribution of relapses in the AIEOP-BFM ALL2000 protocol, 19, 20 the tendency toward an increased percentage of extramedullary relapse localization (either isolated or combined) was observed.
Interestingly, even if the worst outcome was observed for patients with the combination of hiCRLF2 and P2RY8-CRLF2 fusion, the latter turned out to be a poor prognostic factor regardless of CRLF2 over-expression by the Cox model, with a threefold increase in the risk of relapse for positive versus negative patients even after adjusting for main prognostic features. Also the data of the OS analysis after 5 years observation time corroborated the finding that P2RY8-CRLF2 is a stronger prognostic marker than CRLF2 over-expression.
Moreover, P2RY8-CRLF2 fusion also proved to be a significant factor of poor outcome when patients with the favorable factors t(12;21) and DNA index 1.16-1.6 were excluded from the analysis (Supplementary Figure 4) .
In order to understand how to transfer the prognostic impact of this CRLF2 alteration into clinical practice, P2RY8-CRLF2 fusion was analyzed within the non-HR subgroups according to protocol stratification. In particular, it is relevant that the EFS and CIR of the P2RY8-CRLF2 fusion-positive patients in the IR group was similar to that of HR patients in the AIEOP-BFM ALL2000 study and that their OS was significantly reduced. 15 Importantly, this was not the case for SR patients.
The impact of P2RY8-CRLF2 fusion in the Italian cohort was validated in a similar number of patients enrolled in the AIEOP-BFM ALL2000 protocol in Germany, further supporting the evidence that the detection of P2RY8-CRLF2 in MRD-based IR patients would potentially qualify them for a high risk-based treatment. Overall, among IR patients in AIEOP and BFM cohorts, 21 out of 26 P2RY8-CRLF2 fusion-positive patients were treated in the IR prednisone arm, which is available to all patients in the new current AIEOP-BFM ALL2009 protocol. Three out of the twenty six patients were highly MRD-positive at TP1 (d33) and still positive at TP2 (d78 (ref.15) ; a new criterion for HR in the current protocol) and 2/3 relapsed. Indeed, 13/23 relapsing patients would still not have been stratified by these means as HR patients in the current AIEOP-BFM ALL2009 protocol.
In agreement with emerging evidence of mutual collaboration among several genomic lesions leading to constitutive activation of the JAK2/STAT5 pathway, [10] [11] [12] [13] we found additional genomic abnormalities (CRLF2, JAK2 mutations and IKZF1 deletions) in hiCRLF2-and/or P2RY8-CRLF2-positive patients. However, the limited numbers for each of the combinations of these aberrations prevent any prognostic indication from being drawn.
Here, for the first time, we report the analysis on CRLF2 alterations at relapse of childhood BCP-ALL. A total of 33 of the 79 relapses occurring during the observation time of the study were evaluated for CRLF2-expression levels. Samples at relapse showed a median value of CRLF2 expression that was slightly higher than the respective samples at diagnosis (2.60 vs 1.25). Interestingly, no de novo P2RY8-CRLF2 fusion genes were detected in the 26 relapse cases for which the diagnostic correlate had been tested. On the contrary, two positive patients at diagnosis (with low CRLF2 expression levels) lost the P2RY8-CRLF2 fusion at relapse. This is an indirect clue that the deletion, even though it is a strong marker of poor prognosis as described above, is not a primary lesion and can be acquired during the progression of the pre-leukemic clone and thus can contribute to the overt disease. Moreover, like P2RY8-CRLF2, JAK2 mutations appear to be secondary lesions; both do not remain stable at relapse in all cases.
In conclusion, we have shown that childhood BCP-ALL patients with the P2RY8-CRLF2 fusion have a very poor outcome when treated by the AIEOP-BFM approach that could justify a shift from the MRD-based intermediate to the high-risk group. It remains to be demonstrated that a high risk-based therapy could be effective in preventing relapse for these patients. In the long run, alternative therapies that interfere with the activation of the JAK2/STAT5 signaling pathway may hold a promise for treatment of these patients.
